GENSCRIPT BIO (01548): Legend Announces Presentations at 2025 ASH Annual Meeting

Stock News12-07

GENSCRIPT BIO (01548) announced that Legend Biotech ("Legend," an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6, 2025 (New York Time), disclosing clinical and translational research data from long-term follow-up of the CARTITUDE-1 and CARTITUDE-4 studies for CARVYKTI (ciltacabtagene autoleucel, cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The latest results from the Phase III CARTITUDE-4 study were also presented via an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. Additionally, six poster presentations showcased CARVYKTI's durability of response across different subgroups and real-world evidence. Legend further presented first-in-human trial data for its dual-target allogeneic CAR-T candidate, LUCAR-G39D, in an oral session at the ASH Annual Meeting.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1160174342?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-07 19:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1160174342","market":"us","top_or_hot":-1,"title":"GENSCRIPT BIO (01548): Legend Announces Presentations at 2025 ASH Annual Meeting","media":"Stock News","content":"<p>GENSCRIPT BIO (01548) announced that Legend Biotech (\"Legend,\" an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6, 2025 (New York Time), disclosing clinical and translational research data from long-term follow-up of the CARTITUDE-1 and CARTITUDE-4 studies for CARVYKTI (ciltacabtagene autoleucel, cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The latest results from the Phase III CARTITUDE-4 study were also presented via an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. Additionally, six poster presentations showcased CARVYKTI's durability of response across different subgroups and real-world evidence. Legend further presented first-in-human trial data for its dual-target allogeneic CAR-T candidate, LUCAR-G39D, in an oral session at the ASH Annual Meeting.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENSCRIPT BIO (01548): Legend Announces Presentations at 2025 ASH Annual Meeting</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENSCRIPT BIO (01548): Legend Announces Presentations at 2025 ASH Annual Meeting\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-07 19:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENSCRIPT BIO (01548) announced that Legend Biotech (\"Legend,\" an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6, 2025 (New York Time), disclosing clinical and translational research data from long-term follow-up of the CARTITUDE-1 and CARTITUDE-4 studies for CARVYKTI (ciltacabtagene autoleucel, cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The latest results from the Phase III CARTITUDE-4 study were also presented via an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. Additionally, six poster presentations showcased CARVYKTI's durability of response across different subgroups and real-world evidence. Legend further presented first-in-human trial data for its dual-target allogeneic CAR-T candidate, LUCAR-G39D, in an oral session at the ASH Annual Meeting.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000320264.USD","symbol_name":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","start_time":0,"source_url":"","article_id":"1160174342","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1160174342","pubTimestamp":1765105695,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENSCRIPT BIO (01548) announced that Legend Biotech (\"Legend,\" an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000320264.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) ACC","01548":"金斯瑞生物科技","ASH":"Ashland","HK0000306685.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) INC","HK0000320223.HKD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (HKD) ACC","BK1576":"医药外包概念","BK1141":"生命科学工具和服务","LU2463526074.USD":"NORDEA 1 - GLOBAL CLIMATE ENGAGEMENT \"BP\" (USD) ACC","BK4109":"特种化学制品","BK1583":"高瓴概念","HK0000306701.USD":"TAIKANG KAITAI CHINA NEW OPPORTUNITIES FUND \"A\" (USD) INC"},"translate_title":"金斯瑞生物(01548)：联想宣布在2025年ASH年会上发表演讲","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ASH":1,"01548":1},"content_text":"GENSCRIPT BIO (01548) announced that Legend Biotech (\"Legend,\" an associate company whose American Depositary Shares are listed on Nasdaq Global Select Market) issued a press release on December 6, 2025 (New York Time), disclosing clinical and translational research data from long-term follow-up of the CARTITUDE-1 and CARTITUDE-4 studies for CARVYKTI (ciltacabtagene autoleucel, cilta-cel) in patients with relapsed or refractory multiple myeloma (RRMM). The latest results from the Phase III CARTITUDE-4 study were also presented via an oral presentation at the 2025 American Society of Hematology (ASH) Annual Meeting. Additionally, six poster presentations showcased CARVYKTI's durability of response across different subgroups and real-world evidence. Legend further presented first-in-human trial data for its dual-target allogeneic CAR-T candidate, LUCAR-G39D, in an oral session at the ASH Annual Meeting.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1160174342","isCrawlerRequest":true}